[BLACKBIRDSR-71]

THE PUECE OF SHIT CEO WILL REVERSE AGAIN NEXY WEEK, HE FUCKED INVESTORS ALL HIS CAREER

[BLACKBIRDSR-71]

REVERSE THIS SCAM HOAX PIECE OF SHIT AND FILL YOUR POCKETS CEO BASTARD

[BLACKBIRDSR-71]

THE PIECE OF SHIT CEO FUCKED EVERYONE UP THE ASS ONCE AGAIN JUST LIKE THAT PUECE OF SHIT FITZGERALD RNAZ

[Tom turtles]

Buy a Cuspid # for $100 and come up with some bogus product like microwave hot water tanks or solar panels ...that are actually a couple mirrors in your basement...

[Tom turtles]

Hahahaha.....
What a piece of crap

[tw0122]

In consideration of this extension, and the Company not achieving the minimum patient enrollment, by July 1, 2022, as set out in the second amendment to the Eisai License Agreement, the Company agreed to pay a one-time payment to Eisai of $1,250,000 (the “Extension Payment”) as follows: (i) $400,000, (ii) $425,000 within 10 days from August 19, 2024 and (iii) $425,000 upon completion of a 10 million dollar capital raising, but in no event later than September 1, 2024. To date, the Company has paid the full Extension Payment to Eisai, and no payments are currently outstanding.

[tw0122]

The Preferred Stock is convertible, at the option of the holders and, in certain circumstances, by the Company, into the Common Stock, as determined by dividing the net purchase price of $90 per share by the conversion price of $0.17, at the option of the holders. The conversion price can be adjusted pursuant to the Certificates of Designation for stock dividends and stock splits, subsequent rights offering, pro rata distributions of dividends or the occurrence of a fundamental transaction. The holders of the Preferred Stock have the right to require the Company to redeem their shares of preferred stock for cash at 100% of the stated value of such shares commencing after the earlier of the receipt of stockholder approval of the Amendment and 60 days after the Closing Date and until 90 days after the Closing Date. The Company has the option to redeem the Preferred Stock for cash at 100% of the stated value commencing after the 90th day following the Closing Date, subject to the holders’ rights to convert the shares prior to such redemption.

[Acehole]

New round of bagholders getting sucked in.

[trendzone]

Can't argue with that not being the case, it's an outright major crime that the SEC lets these criminals in their cheap suits getaway with it,day in and day out, sure many start out believing they can become something that could turn into something good,but most turn into a toxic cesspools with no way out,other than becoming the self-centered selfish toxic slobs they become, and think they are doing nothing wrong ripping off the public and lining their pockets and over compensating themselves with greedy payouts,that none of them deserve,when the company's are using burning through cash to support their scam until the worthless brainless SEC some times do their usual half-ass job of shutting them down,after the retail public ends up losing many millions,to be one of them I guess you have to have a few bucks buyout a shell company and hype of some kind of BS that you have something great,and sucker in the public to believe the BS, and have a few cheap suits,for when you get involved with the toxic note dilution lenders,and the pump and dump promoters.

[Acehole]

There is a reason many institutional investors won't invest in sub $5 stocks. They are generally all bottom feeding pump and dump scams. Dilution followed by reverse split followed by more dilution etc etc until Nasdaq finally boots them off the exchange. Jackass CEO and management give themselves bonuses just prior to bankruptcy and ride off into the sunset with all the money stole and have zero liability for the fraud they committed. Man, what a racket. How do I get in on it?

[trendzone]

Funny how they are trying to scare share holders into voting yes for a RS, mean while they screwed over any one who got stuck in the last one they just did in May, $5.00 to $0.15 in just three months,great investment only if you were short, or a naked shorting hedge fund criminal enterprise, wouldn't be surprised if they themselves shorted their own stock back then, sure they want a RS so they can keep the toxic slob formula in place,and keep their over paid salaries from getting hit and cut in half,and keep sucking money out of it on the backs of the public.

[Law of Averages]

I wonder if this will hit $1.00 it's moving pretty fast

[Awl416]

8k was released

[Law of Averages]

Looks like a short squeeze has started after hours .27 and climbing

[georgie18]

ALLR...18... https://schrts.co/AshjZBCw...Could get squeezed here with some tight bands...🥳

[Law of Averages]

BB bands are super tight on ALLR this could see a hard bounce up.

[TheOTCstocksGuy]

Absolute trash!! Been saying it for months but no one listens as usual!!

[gdog]

pretty much

[just Scottie]

In the toilet now

[gdog]

ALLR recieves a well notice trade accordingly

[just Scottie]

I haven’t been a shareholder long enough I guess. I didn’t get an email.
I guess to vote on the RS, stock options lol and new officers

[gdog]

gosh i don't know I usually just delete without looking much what does it look like?

[just Scottie]

Did u get an email to vote for the split?

[gdog]

agree

[just Scottie]

Getting an extension and postpone the split and get some good news is the only way we stave off the wolves

[just Scottie]

Someone just said short shares are over $3 million

[gdog]

yup lets see how far they take it down am also done buying.

[just Scottie]

I’m afraid to ave down again
Every time I have it plunges more

[just Scottie]

Yes big time

[gdog]

lol i was typing as you were posting yes we need g/news

[gdog]

yes I'm down a good bit also we need good news and hurry

[just Scottie]

Company needs to majorly combat this with some good news

[gdog]

that was ending 6-30

[gdog]

https://www.marketbeat.com/stocks/NASDAQ/ALLR/short-interest/
700,000 sold short in the last 2 wks

[just Scottie]

They are doing a good job. Lost my ass
Doesn’t help if the company may be selling too

[gdog]

I added a few today gulp all markets down today. the shorts are trying to destroy it

[just Scottie]

Selling is relentless brother. Where the hell does it all come from

[just Scottie]

That will be great

[gdog]

understood still think buyout

[just Scottie]

Well unfortunately they need to maintain a dollar to stay on the daq

[gdog]

17.5 m outstanding don't let people worry you about an RS

[just Scottie]

Gonna be tough sledding here. So much downward pressure due to the RS threat
Shorts and pump and dumpers have the upper hand

[gdog]

few hundred isn't wwhat I'm looking for I wants k's
look https://investorshub.advfn.com/Bottom-Swing-Plays-29717

[just Scottie]

Everyone dumped from 18 cents
Hoping news of new trial comes today

[gdog]

BUY out coming ??????????

[Law of Averages]

Agreed. ALLR moving up hella quick.

[just Scottie]

Shorty could shit themselves here soon.

[Zardiw]

Stop sugar coating it.......say it like it is...........

Z

[just Scottie]

$ALLR THESE PARTS OF THE LAST PR STAND OUT TO ME. TELLS ME THEY ARE ACTIVELY LOOKING FOR PARTNERS OR BUYOUT. THEY HAVE GOTTEN VERY GOOD RESULTS, SO GOOD THEY STOPPED THE LAST TRIAL EARLY. YOU DON’T DO THAT UNLESS THE PATIENTS HAVE BENIFITTED. FDA COULD COME I AND FAST FRACK THIS. ITS JUST MEANT TO EXTEND LIFE ON ADVANCED OVARIAN CANCER PATIENTS. SOFAR THEY HAVE PROVED IT SHRINKS TUMOR SIZE.
“Not only does the safety profile stand out when compared to chemotherapies, which is often the alternative for this patient group, but the safety metrics are indeed also favorable when compared to first-generation PARP inhibitors. As we see it, stenoparib may represent the next-generation alternative for advanced ovarian cancer patients. Therefore, we are aggressively working with Dr. Moore and other leading experts to design a trial that will help advance and quicken stenoparib’s clinical progress toward registration with the FDA.”

“After conducting a detailed review of the stenoparib monotherapy trial data, including the data announced today, the Company has concluded that these data may be of significant interest among key oncologists, potential commercial partners, and other relevant stakeholders and therefore warrant presentation within a high-level scientific conference. Further release of these clinical data is intended to be staged to comply with the common rules of scientific conferences, which do not allow data to be published before the event.”

The PARP inhibitor market is expected to reach $22 billion in revenue by 2028, and has historically seen significant partnerships and acquisitions.

For example, one significant acquisition included a multi-asset deal potentially totaling $1.5 billion, which featured an advanced PARP inhibitor.

Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.